New drug combo aims to wipe out hepatitis c in Hard-to-Treat patients
NCT ID NCT07316842
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 30 adults with chronic hepatitis C (genotype 3) and mild to moderate liver fibrosis who are taking ravidasvir and sofosbuvir as part of their regular care. Researchers will check if the virus is undetectable 12 weeks after treatment ends (SVR12). The goal is to see how well this drug combination works in a real-world setting.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ravidasvir and sofosbuvir
- What this could lead to
- If successful, this could confirm that the combination of ravidasvir and sofosbuvir effectively clears the hepatitis C virus in people with genotype 3 and mild liver damage.
- What could go wrong
- This is a small observational study with only 30 participants, so results may not apply to everyone. It is not a randomized trial, and the long-term durability of the response beyond 12 weeks is not assessed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
30 people
The number who actually took part.
- Started
-
Sep 2025
- Expected to finish
-
Feb 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with chronic hepatitis C virus infection genotype 3 with fibrosis stage F0-F2 were selected for this non-interventional study. These patients represent an important group with a high probability of successful therapy response and relatively low risk of complications, making them ideal candidates for studying the efficacy and safety of a short-term treatment regimen with ravidasvir and sofosbuvir. A similar patient population showed a high rate of sustained virological response (93.42%) in the EASE clinical trial (NCT05757700) with an 8-week therapy regimen. Despite the presence of significant data on treatment of chronic hepatitis C overall, detailed descriptions of disease epidemiology depending on virus genotype, fibrosis stage, and treatment efficacy in patients at early disease stages in real clinical practice are limited.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient informed consent for the collection and use of data in scientific research. * Diagnosed chronic hepatitis C (genotype 3). * Fibrosis stage F0-F2 according to METAVIR, confirmed by liver biopsy or liver elastography (results of performed studies must be no older than 3 months at the start of antiviral therapy). * Signed informed consent. * Age ≥18 years. * Antiviral therapy with ravidasvir and sofosbuvir initiated as part of routine clinical practice. Exclusion Criteria: * Significant concomitant liver diseases considered relevant by the investigator (hepatitis B, hemochromatosis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hepatocellular carcinoma). * Presence of other active viral infections (e.g., hepatitis B, HIV). * If the patient has received other antiviral treatment for hepatitis C within the last 6 months. * Pregnancy or breastfeeding. * Alcohol or drug dependence that may interfere with adherence to the treatment regimen.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic hepatitis C genotype 3 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center of Target Therapy LLC.
Moscow, 125008, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.